Botulinum toxin type a
Nuceiva (botulinum toxin type a) is a protein pharmaceutical. Botulinum toxin type a was first approved as Nuceiva on 2019-09-27. It is used to treat blepharospasm, dystonia, fissure in ano, genetic skin diseases, and muscle rigidity amongst others in the USA. It has been approved in Europe to treat skin aging.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1305 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscle spasticity | D009128 | HP_0001257 | — | 8 | 18 | 46 | 26 | 77 | 167 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 8 | 18 | 26 | 27 | 35 | 108 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 5 | 11 | 29 | 15 | 37 | 92 |
| Cerebral palsy | D002547 | — | G80 | 3 | 10 | 21 | 7 | 48 | 85 |
| Dystonia | D004421 | HP_0001332 | G24 | 6 | 13 | 15 | 11 | 30 | 70 |
| Torticollis | D014103 | HP_0000473 | F45.8 | 5 | 12 | 13 | 12 | 25 | 65 |
| Dystonic disorders | D020821 | — | G24 | 6 | 12 | 15 | 9 | 26 | 63 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 3 | 9 | 15 | 14 | 24 | 62 |
| Syndrome | D013577 | — | — | 13 | 24 | 10 | 5 | 9 | 53 |
| Urinary incontinence | D014549 | HP_0000020 | R32 | 4 | 7 | 15 | 12 | 10 | 44 |
Show 145 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sialorrhea | D012798 | HP_0002307 | K11.7 | — | 5 | 9 | — | 2 | 13 |
| Traumatic brain injuries | D000070642 | — | S06 | — | 4 | 5 | — | 3 | 11 |
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | 1 | 2 | 1 | — | 5 | 9 |
| Equinus deformity | D004863 | — | — | — | 1 | 1 | — | 7 | 9 |
| Tennis elbow | D013716 | EFO_1001896 | M77.1 | — | — | 5 | — | 3 | 8 |
| Talipes | D000070558 | HP_0001883 | Q66.1 | — | 1 | 1 | — | 6 | 8 |
| Dysphonia | D055154 | — | R49.0 | 2 | 3 | 1 | — | 4 | 7 |
| Hoarseness | D006685 | HP_0001609 | R49.0 | 2 | 3 | 1 | — | 4 | 7 |
| Ganglion cysts | D045888 | — | M67.4 | 2 | 4 | 2 | — | 1 | 7 |
| Botulism | D001906 | EFO_0005542 | A05.1 | 3 | 1 | 1 | — | 3 | 7 |
Show 59 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Muscle cramp | D009120 | HP_0003394 | — | 1 | 3 | — | — | 3 | 6 |
| Contracture | D003286 | HP_0001371 | M62.4 | — | 2 | — | — | 3 | 5 |
| Esophageal motility disorders | D015154 | — | K22.4 | — | 1 | — | — | 3 | 4 |
| Myalgia | D063806 | HP_0003326 | M79.1 | — | 1 | — | — | 2 | 3 |
| Abdominal hernia | D046449 | — | K46 | — | 1 | — | — | 2 | 3 |
| Internal hernia | D000082122 | — | — | — | 1 | — | — | 2 | 3 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | 2 | 3 |
| Neck pain | D019547 | HP_0030833 | M54.2 | 2 | 1 | — | — | 1 | 3 |
| Carpal tunnel syndrome | D002349 | EFO_0004143 | G56.0 | — | 3 | — | — | — | 3 |
| Prostatic neoplasms | D011471 | — | C61 | 2 | 1 | — | — | — | 3 |
Show 77 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhagic stroke | D000083302 | — | — | 1 | — | — | — | 2 | 3 |
| Complex regional pain syndromes | D020918 | EFO_1001998 | — | 1 | — | — | — | 2 | 3 |
| Reflex sympathetic dystrophy | D012019 | EFO_1001147 | G90.5 | 1 | — | — | — | 2 | 3 |
| Neurologic gait disorders | D020233 | HP_0003376 | R26.1 | 1 | — | — | — | 1 | 2 |
| Skin abnormalities | D012868 | HP_0000951 | Q82.9 | 1 | — | — | — | 1 | 2 |
| Intracranial sinus thrombosis | D012851 | — | — | 1 | — | — | — | — | 1 |
| Internal carotid artery dissection | D020215 | — | — | 1 | — | — | — | — | 1 |
| Vertebral artery dissection | D020217 | — | I77.74 | 1 | — | — | — | — | 1 |
| Vascular headaches | D014653 | — | — | 1 | — | — | — | — | 1 |
| Bursitis | D002062 | EFO_1000941 | M71.9 | 1 | — | — | — | — | 1 |
Show 14 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Diffuse esophageal spasm | D015155 | EFO_1001785 | K22.4 | — | — | — | — | 3 | 3 |
| Ischemic stroke | D000083242 | — | — | — | — | — | — | 2 | 2 |
| Flushing | D005483 | — | R23.2 | — | — | — | — | 2 | 2 |
| Movement disorders | D009069 | HP_0100022 | — | — | — | — | — | 2 | 2 |
| Pancreatectomy | D010180 | EFO_0002581 | — | — | — | — | — | 1 | 1 |
| Treatment outcome | D016896 | — | — | — | — | — | — | 1 | 1 |
| Muscle tonus | D009129 | — | — | — | — | — | — | 1 | 1 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | — | 1 | 1 |
| Physical therapy modalities | D026741 | — | — | — | — | — | — | 1 | 1 |
| Anticholinergic syndrome | D064807 | — | — | — | — | — | — | 1 | 1 |
Show 51 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Botulinum toxin type a |
| INN | — |
| Description | Botulinum toxin, or botulinum neurotoxin, is a highly potent neurotoxic protein produced by the bacterium Clostridium botulinum and related species. It prevents the release of the neurotransmitter acetylcholine from axon endings at the neuromuscular junction, thus causing flaccid paralysis. The toxin causes the disease botulism. The toxin is also used commercially for medical and cosmetic purposes.
|
| Classification | Neurotoxin |
| Drug class | fluoroquinolone derivatives, nonantibacterial indication (e.g., antineoplastic antibiotics) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297862 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00083 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,528 documents
View more details
Safety
Black-box Warning
Black-box warning for: Daxxify, Dysport
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,532 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use